Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology


Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable Therapeutics

Read more:
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Related Posts